14 burnett case 3 j - isgio.org 2 - burnett-choti case.pdf · distal cholangiocarcinoma...
TRANSCRIPT
Distal Cholangiocarcinoma
International Society of Gastrointestinal OncologyNovember 1-2, 2018
Case Presentation
Atuhani Burnett, MD, PhD, Michael Choti, MD, FACS
• 73 y/o M with 50 lb weight loss 4 months, jaundice, pruritus • MRCP: mild to moderate intrahepatic biliary duct dilatation, no soft tissue mass• ERCP: moderate mid CBD stricture, brushings sent, stent placed• Malignant cells found on brushings
• PMH: CAD s/p 2vCABG, HTN, HLD, GERD
• CA19-9 = 55, Tbili 8.0 -> normalized to 1.5 after stent
JM 73yM
Which of the following further diagnostic studies would you recommend?
A. PET ScanB. Staging laparoscopy and cytology washingsC. Additional biopsy with EUS/FNAD. No additional studies
ARS Question
If biopsy were non-diagnostic or negative, which of the following further diagnostic studies would you recommend?
A. PET ScanB. Staging laparoscopy and cytology washingsC. EUS/FNAD. No additional studies
ARS Question
What would you recommend at this point?
A. Surgery (pancreaticoduodenectomy)B. Neoadjuvant chemotherapyC. Neoadjuvant chemoradiation therapy
ARS Question
• Patient received up front surgery• Operative findings:
– Procedure: pancreaticoduodenectomy– No contact with portal SMV or SMA– End to side pancreaticojejunostomy– soft gland, 3mm duct, duct-to-mucosa anastomosis, no stent– End to side hepaticojejunostomy– Retrocolic gastrojejunostomy
• Patient did well post op, drain amylase 300 on day 1, resolved by day 3, with low drain outputs
• Diet tolerated, out of bed ambulating, discharged by PO day 7, without drain• Final path: intestinal type adenocarcinoma consistent with cholangiocarcinoma,
2cm ypT3N0, negative margins
JM 73yM
What would you recommend at this point?
A. Adjuvant chemotherapyB. Adjuvant chemoradiation therapyC. No post-operative therapy
ARS Question
If you recommend postoperative chemotherapy alone, which regimen would you advise?
A. GemcitabineB. Gemcitabine + CapecitabineC. Gem + nab-paxlitaxelD. Gem + cisplatinE. FORFIRINOXF. FOLFOXG. Something Else
ARS Question
• RCT, N=410, locally advanced/metastatic biliary tract CA, gem vs gem + cisplatin
ABC-02 RCT
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A,
Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. N Engl J Med. 2010 Apr 8;362(14):1273-81.
11.7 m vs 8.1 m
• RCT, N=410, locally advanced/metastatic biliary tract CA, gem vs gem + cisplatin• extra-hepatic N=73
ABC-02 RCT
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. N Engl J Med. 2010 Apr 8;362(14):1273-81.
• Retrospective, NCDB, propensity score matched
Distal Cholangio, +/- Adjuvant Chemo
Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.Hester C, Nassour I, Adams-Huet B, Augustine M, Choti MA, Minter RM, Mansour JC, Polanco PM, Porembka MR, Wang SC, Yopp AC. J Gastrointest Surg. 2018 Jul 20.
N=500:50025.2 m O vs 31.2 m ATHR 0.79 (0.67 – 0.94)
N=348:34829.5 m CT vs 32.1 m CRT
• Still accruing
ACTICCA-1 trial
Gallbladder CACholangio CA
Curative intent resection
GemcitabineCisplatin Capecitabine